|
|
Article: Merck KGaA acquires manufacturing rights for Stimuvax from Oncothyreon.
- Article from:
- PR Newswire
- Article date:
- December 18, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SEATTLE, Dec. 18 /PRNewswire-FirstCall/ -- Oncothyreon Inc. (TSX:ONY) announced today that Merck KGaA of Darmstadt, Germany has licensed the right to manufacture Stimuvax(R) and, through its affiliate EMD Serono Canada Inc., purchased current inventory and certain assets utilized for the manufacture of Stimuvax from Oncothyreon for consideration which includes net payments to Oncothyreon totaling approximately US $13 million. Merck KGaA currently holds the clinical development and commercialization rights for Stimuvax under license from Oncothyreon. Stimuvax is a therapeutic vaccine in Phase 3 clinical development for non-small cell lung cancer.
In conjunction ...
Related newspaper, magazine, and journal articles:
|
|
Article: Equant provides business-critical network services to ...
M2 Presswire;
January 21, 2003 ;
700+ words
... ... business-critical network services to Merck KGaa and other pharmaceutical-life sciences ... LAN Access services to more than 100 Merck KGaA locations worldwide(C)1994-2003 ... multimillion-dollar contract extension with Merck KGaA to continue managing and monitoring the ...
|
|